.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

MOZOBIL Drug Profile

« Back to Dashboard
Mozobil is a drug marketed by Genzyme and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-seven patent family members in twenty-nine countries.

The generic ingredient in MOZOBIL is plerixafor. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the plerixafor profile page.

Summary for Tradename: MOZOBIL

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Drug Prices: :see details

Pharmacology for Tradename: MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYes6,987,102► subscribe ► subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYes► subscribe► subscribe
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 2008RXYes7,897,590► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MOZOBIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme
MOZOBIL
plerixafor
SOLUTION;SUBCUTANEOUS022311-001Dec 15, 20085,583,131► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: MOZOBIL

Drugname Dosage Strength RLD Submissiondate
plerixaforInjection24 mg/1.2 mL vials (20 mg/mL)Mozobil12/17/2012

Non-Orange Book Patents for Tradename: MOZOBIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,750Methods to mobilize progenitor/stem cells► subscribe
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity► subscribe
7,935,692Methods to mobilize progenitor/stem cells► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MOZOBIL

Country Document Number Estimated Expiration
Norway305984► subscribe
Hong Kong1063005► subscribe
Japan3375961► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MOZOBIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009 00052Denmark► subscribe
0120014 00064Estonia► subscribePRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009
033Luxembourg► subscribe92033, EXPIRES: 20240731
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc